What is the average price target for NASUS PHARMA LTD (NSRX) stock?
8 analysts have analysed NSRX and the average price target is 20.91 USD. This implies a price increase of 771.25% is expected in the next year compared to the current price of 2.4.
NASUS PHARMA LTD (NSRX) Forecast, Price Target & Analyst Ratings
NYSEARCA:NSRX • IL0012181553
Current stock price
2.4 USD
-0.36 (-13.04%)
At close:
2.4198 USD
+0.02 (+0.83%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NASUS PHARMA LTD (NSRX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2025
- EPS Estimate
- -$0.04
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$20.91
Upside
+ 771.25%
From current price of $2.40 to mean target of $20.91, Based on 8 analyst forecasts
Low
$19.19
Median
$20.91
High
$23.10
Price Target Revisions
1 Month
0.00%
3 Months
-6.82%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for NSRX. The average price target is 20.91 USD. This implies a price increase of 771.25% is expected in the next year compared to the current price of 2.4.
The average price target has been revised downward by 6.82% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
NSRX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about NSRX.
In the previous month the buy percentage consensus was at a similar level.
NSRX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-26 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-18 | Citizens | Initiate | Market Outperform |
| 2025-09-29 | Laidlaw & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2025
- EPS Estimate
- -$0.04
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- N/A
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2025 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | ||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.1K | -2.3K 43.90% | -2.2K 4.35% | N/A -248,061.36% | N/A -249.90% | N/A -61.89% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -129.93% | N/A -13.65% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.04 | -0.07 | -0.14 | -0.39 |
| Revenue Q2Q % growth | N/A | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -270.3K | -705.84K -141,068.00% | -1.809M | -4.8M -436,274.55% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-1,725.76%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NASUS PHARMA LTD / NSRX Forecast FAQ
What are the consensus estimates for NSRX stock next earnings?
The consensus EPS estimate for the next earnings of NASUS PHARMA LTD (NSRX) is -0.04 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for NSRX stock?
The consensus rating for NASUS PHARMA LTD (NSRX) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.